Comparative Pharmacology
Head-to-head clinical analysis: ATOVAQUONE versus LAMPIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATOVAQUONE versus LAMPIT.
ATOVAQUONE vs LAMPIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atovaquone is a hydroxynaphthoquinone that selectively inhibits mitochondrial electron transport chain complex III (cytochrome bc1 complex) in parasites, thereby disrupting pyrimidine synthesis and energy metabolism.
Inhibits the enzyme G6PD (glucose-6-phosphate dehydrogenase) in Trypanosoma cruzi, leading to oxidative stress and parasite death.
750 mg oral suspension twice daily for treatment of mild-to-moderate Pneumocystis jirovecii pneumonia; 1500 mg oral suspension once daily for prophylaxis.
Nifurtimox (Lampit) for Chagas disease: adult dose 8-10 mg/kg/day orally in 3 divided doses for 90 days. For Chagas disease in children: 15-20 mg/kg/day orally in 3 divided doses for 90 days.
None Documented
None Documented
Clinical Note
moderateAtovaquone + Indinavir
"The serum concentration of Indinavir can be decreased when it is combined with Atovaquone."
Clinical Note
moderateAtovaquone + Artemether
"The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Artemether."
Clinical Note
moderateAtovaquone + Lumefantrine
"The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Lumefantrine."
Clinical Note
moderateAtovaquone + Dapsone
Terminal elimination half-life is approximately 2-3 days (67 hours) in adults, prolonged in renal or hepatic impairment.
Terminal elimination half-life is approximately 20 hours. In hepatic impairment, half-life may be prolonged by up to 2-fold.
Primarily fecal (>94%) as unchanged drug; renal excretion is minimal (<1%).
Renal excretion of unchanged drug accounts for 10% of the dose; biliary/fecal excretion accounts for approximately 90%, mainly as metabolites.
Category A/B
Category C
Antiprotozoal
Antiprotozoal
"The risk or severity of adverse effects can be increased when Atovaquone is combined with Dapsone."